➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Dow
Baxter
Johnson and Johnson
Colorcon

Last Updated: October 23, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ENTECAVIR

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Entecavir

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00035633 A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Positive for Hepatitis B E Antigen Completed Bristol-Myers Squibb Phase 3 2001-12-01 The purpose of this clinical research study is to assess the safety effectiveness of entecavir, as compared to lamivudine, in the treatment of adults with chronic hepatitis B infection who are hepatitis B e antigen positive.
NCT00035789 A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen Completed Bristol-Myers Squibb Phase 3 2001-11-01 The purpose of this clinical research study is to assess the safety and effectiveness of entecavir, as compared to lamivudine, in the treatment of adults with chronic hepatitis B infection who are hepatitis B e antigen negative.
NCT00036608 A Phase III Study of Entecavir vs Lamivudine in Chronic Hepatitis B Subjects With Incomplete Response to Lamivudine Completed Bristol-Myers Squibb Phase 3 2002-01-01 The purpose of this clinical research study is to assess the safety and effectiveness of switching to entecavir compared to continued lamivudine in patients with chronic hepatitis B.
NCT00051038 Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients Completed Bristol-Myers Squibb Phase 2/Phase 3 2002-09-01 The purpose of this clinical research study is to assess the safety and effectiveness of entecavir, when being added to lamivudine, in the treatment of adults with chronic hepatitis B infection who are co-infected with HIV.
NCT00065507 Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation Completed Bristol-Myers Squibb Phase 3 2003-08-01 This is a phase IIIb comparative study of entecavir 1.0 mg once daily (QD) vs. adefovir 10 mg QD in patients who have chronic hepatitis B infection and hepatic decompensation. The patients are treated for 96 weeks after the last subject is randomized.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Entecavir

Condition Name

Condition Name for Entecavir
Intervention Trials
Chronic Hepatitis B 78
Hepatitis B, Chronic 38
Hepatitis B 38
Hepatocellular Carcinoma 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Entecavir
Intervention Trials
Hepatitis B 187
Hepatitis 172
Hepatitis B, Chronic 144
Hepatitis A 141
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Entecavir

Trials by Country

Trials by Country for Entecavir
Location Trials
China 249
United States 213
Korea, Republic of 59
Japan 35
Taiwan 31
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Entecavir
Location Trials
California 21
New York 17
Maryland 15
Texas 14
Florida 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Entecavir

Clinical Trial Phase

Clinical Trial Phase for Entecavir
Clinical Trial Phase Trials
Phase 4 88
Phase 3 29
Phase 2/Phase 3 3
[disabled in preview] 49
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Entecavir
Clinical Trial Phase Trials
Completed 58
Recruiting 53
Not yet recruiting 33
[disabled in preview] 44
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Entecavir

Sponsor Name

Sponsor Name for Entecavir
Sponsor Trials
Bristol-Myers Squibb 32
National Taiwan University Hospital 11
Tongji Hospital 8
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Entecavir
Sponsor Trials
Other 327
Industry 107
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
McKinsey
Moodys
Boehringer Ingelheim
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.